

## neffy® (epinephrine nasal spray) – Expanded indication

- On March 5, 2025, <u>ARS Pharmaceuticals announced</u> the FDA approval of <u>neffy (epinephrine nasal spray)</u>, for emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients aged 4 years and older who weigh 15 kg or greater.
  - Neffy was previously approved for this indication in adult and pediatric patients who weigh 30 kg or greater.
- In addition to the expanded indication, the FDA approved a new 1 mg/0.1 mL nasal spray.
  - Neffy is also available as a 2 mg/0.1 mL nasal spray.
- The use of neffy is supported by extrapolation from the clinical pharmacology studies in adults that compared the pharmacokinetic/pharmacodynamic profile of neffy to epinephrine injection products with established safety and effectiveness for this indication and clinical pharmacology data in pediatric patients aged 4 years and older who weigh 15 kg or greater.
- The recommended dose of neffy for patients weighing 15 kg to less than 30 kg is one spray of neffy 1 mg.
  - In the absence of clinical improvement or if symptoms worsen after the initial treatment, a second dose of neffy may be administered in the same nostril with a second nasal spray starting 5 minutes after the first dose.
- ARS Pharmaceuticals is expected to launch neffy 1 mg by the end of May 2025.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.